All In Biotech

Drug Trial Radar · NCT07407673

Prediction and Prevention of Bloodstream Infections After Kidney Transplantation

Prediction and Prevention of Bloodstream Infections After Kidney Transplantation - The PREDICT Study

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Jan 1, 2027

Primary completion

Jul 2031

Study completion Jul 2041

Sponsor

Lead sponsor
Susanne Dam Nielsen, MD, DMScAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Aarhus University Hospital; Odense University Hospital; Zealand University Hospital; Aalborg University Hospital; Copenhagen University Hospital, Rigshospitalet
First posted
Feb 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Kidney transplant recipients take medicines that suppress the immune system to prevent rejection of the transplanted kidney. As a result, they have a high risk of infections, especially urinary tract infections (UTIs). Some of these infections can spread to the bloodstream and cause serious illness, hospitalization, loss of kidney function, or death. Currently, there is no established strategy to prevent these serious bacterial infections in kidney transplant recipients who are at highest risk. The PREDICT study is investigating whether a low daily dose of the antibiotic pivmecillinam can reduce the risk of bacterial urinary tract infections and bloodstream infections after kidney transplantation. The study includes kidney transplant recipients who have bacteria detected in their urine during the first month after transplantation, as previous research suggests that these patients have a particularly high risk of developing later serious infections. In this randomized, double-blind, placebo-controlled trial, 180 adult kidney transplant recipients will be assigned by chance to receive either pivmecillinam or a matching placebo from 1 to 6 months after transplantation. Neither participants nor study staff will know which treatment has been assigned during the study. All participants will continue to receive standard post-transplant care and monitoring. The main goal of the study is to determine whether prophylactic pivmecillinam can reduce the occurrence of infections caused by Enterobacterales bacteria, including urinary tract infections and bloodstream infections, during the first 6 months after transplantation. The study will also evaluate the effects of treatment on serious clinical outcomes, safety, quality of life, antimicrobial resistance, and long-term kidney transplant outcomes. The main hypothesis is that targeted antibiotic prophylaxis with pivmecillinam in kidney transplant recipients at increased risk of infection will reduce the incidence of Enterobacterales urinary tract infections and bloodstream infections during the high-risk period after transplantation compared with placebo.

Conditions

  • Kidney Transplant Infection
  • Bloodstream Infection
  • Kidney Transplant
  • Kidney Transplant Recipients
  • Infection
  • Urinary Tract Infection(UTI)
  • Urinary Tract Infection Bacterial
  • Antibiotic Prophylaxis
  • Bacteriuria

Interventions

  • PivmecillinamDrug

    Study participants in the intervention arm will receive 400 mg pivmecillinam tablets once daily administered orally. Treatment will be initiated one month post-transplantation and will continue for a total duration of 5 months (months 1-6 post-transplantation).

  • PlaceboDrug

    Study participants in the placebo arm will receive one inactive placebo tablet once daily; the timing, frequency and duration is the same as for the active study drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Enterobacterales Urinary Tract Infections and/or Enterobacterales Bloodstream InfectionsTime frame: Months 1-6 post-transplantation

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Aarhus University Hospital, Department of Nephrology

    Aarhus, Denmark

  • Rigshospitalet, Department of Nephrology

    Copenhagen, Denmark

  • Odense University Hospital, Department of Nephrology

    Odense, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.